Serina Therapeutics (SER) Receives NYSE Deficiency Notice for Low Stockholders' Equity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: NASDAQ.COM
- Insufficient Stockholders' Equity: As of September 30, 2025, Serina Therapeutics reported stockholders' equity of $1.6 million, falling short of the NYSE's minimum requirement of $2 million, indicating severe financial health issues that could jeopardize its continued listing.
- Widening Losses: For the nine months ending September 30, 2025, Serina's net loss increased to $15.85 million, or $1.60 per share, compared to a net loss of $8.4 million, or $1.24 per share in the previous year, highlighting significant challenges in achieving profitability.
- Compliance Plan Requirement: The NYSE notice mandates that Serina submit a plan by February 8, 2026, detailing actions taken to regain compliance; failure to secure approval could initiate delisting proceedings, adversely affecting investor confidence.
- Stock Price Volatility: Although Serina's stock closed slightly higher at $2.69 on Thursday, it fell 1.49% overnight, reflecting market concerns over its financial situation, with a trading range of $1.71 to $7.92 over the past year, indicating market uncertainty.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SER with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SER
Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.720
Low
11.00
Averages
11.00
High
11.00
Current: 2.720
Low
11.00
Averages
11.00
High
11.00
About SER
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Serina Therapeutics Receives FDA Clearance for IND Application
- FDA IND Clearance: Serina Therapeutics announced that its IND application for SER-252 has been cleared by the FDA, allowing the company to proceed with preparations for a planned Phase 1b registrational study, which is expected to significantly advance treatment options for Parkinson's disease patients.
- Stock Surge: Following the FDA clearance announcement, Serina's shares surged over 70% in pre-market trading, reflecting strong market optimism for the therapy, particularly after experiencing a setback in November 2025 when the FDA placed a clinical hold on its trials.
- Trial Design Support: The FDA had previously provided written feedback supporting Serina's proposed registrational trial design under the 505(b)(2) NDA pathway, indicating a clear path forward for the therapy to address significant unmet medical needs.
- Market Sentiment Shift: Following the announcement, investor sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', accompanied by a surge in message volume, indicating strong market interest and potential investment opportunities for SER-252.
Continue Reading
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Results: Meta reported fourth-quarter revenue of $59.89 billion, exceeding analyst expectations of $58.30 billion, indicating robust performance in the recovering advertising market, which is likely to drive further stock price increases.
- Earnings Growth: The company posted adjusted earnings of $8.88 per share, surpassing the forecast of $8.16 per share, reflecting significant improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Stock Price Surge: Following the earnings report, Meta's shares jumped 8.2% in pre-market trading to $723.70, indicating a positive market sentiment towards the company's growth prospects, which may attract more investor interest.
- Optimistic Sales Guidance: Meta's first-quarter sales guidance exceeded market expectations, further solidifying its leadership position in the digital advertising space and suggesting continued benefits from the recovery in advertising spending.
Continue Reading